KNOXVILLE, TN / ACCESSWIRE / May 9, 2016 / Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) will host a live conference call
and webcast to discuss the results of the first quarter 2016, to be held Tuesday May 10, 2016 at 4:00 PM Eastern Time.
To participate in this event, dial 877-407-4019 domestically, or 201-689-8337 internationally, approximately 5 to 10 minutes
before the beginning of the call. Additionally, you can listen to the event online at
www.investorcalendar.com/IC/CEPage.asp?ID=175006 as well as via the Provectus Biopharmaceuticals website
(www.provectusbio.com).
If you are unable to participate during the live webcast, the event archive will be available at www.investorcalendar.com or
www.provectusbio.com.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed
Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry,
www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com or
contact Porter, LeVay & Rose, Inc.
SOURCE: Investor Calendar
